How to buy Adaptive Biotechnologies shares | $46.93

Adaptive Biotechnologies Corporation is a biotechnology business with stocks listed in the US. Adaptive Biotechnologies shares (ADPT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$46.93 – a decrease of 9.21% over the previous week.

How to buy shares in Adaptive Biotechnologies

1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
3. Search for Adaptive Biotechnologies. Find the share by name or ticker symbol: ADPT. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Adaptive Biotechnologies reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of US$46.93, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Adaptive Biotechnologies, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Adaptive Biotechnologies. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

🧪How we chose these brokers

For our Top Picks, we compared our Finder partners using a proprietary algorithm in August 2020. Keep in mind that our top picks may not always be the best for you, and you're encouraged to compare for yourself to find one that works for you. Read our full methodology here to find out more.

How has coronavirus impacted Adaptive Biotechnologies's share price?

Since the stock market crash in March caused by coronavirus, Adaptive Biotechnologies's share price has had significant positive movement.

Its last market close was US$46.93, which is 27.21% up on its pre-crash value of US$34.16 and 208.95% up on the lowest point reached during the March crash when the shares fell as low as US$15.19.

If you had bought US$1,000 worth of Adaptive Biotechnologies shares at the start of February 2020, those shares would have been worth US$755.26 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth US$1,564.18.

Adaptive Biotechnologies share price

Use our graph to track the performance of ADPT stocks over time.

Adaptive Biotechnologies shares at a glance

• Key figures

Information last updated 2020-10-20.

Latest market close	USD$46.93
52-week range	USD$15.19 - USD$54.2
50-day moving average	USD$46.2651
200-day moving average	USD$40.5138
Target price	USD$53.17
PE ratio	44.5603
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-4.344

Get $0 brokerage on US stocks with trades as little as $50 when you join the world’s biggest social trading network.

eToro Share Trading (US stocks)

USD 0

Standard brokerage - US shares

Get $0 brokerage on US stocks with trades as little as $50 when you join the world’s biggest social trading network.

• $0 brokerage for US stocks
• Trades starting from $50
• Fractional shares
• Copy top traders

Go to site

More info

Important: Share trading carries risk of capital loss.

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Adaptive Biotechnologies stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Adaptive Biotechnologies Corporation by TradingView

Adaptive Biotechnologies price performance over time

Historical closes compared with the close of $46.93 on 2020-10-22

1 week (2020-10-22)	0%
1 month (2020-09-29)	-2.31%
3 months (2020-07-29)	22.25%
6 months (2020-04-29)	44.31%

1 year (2019-10-29)	79.12%
2 years (2018-10-25)	N/A
3 years (2017-10-25)	N/A
5 years (2015-10-25)	N/A

Is Adaptive Biotechnologies under- or over-valued?

Valuing Adaptive Biotechnologies stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Adaptive Biotechnologies's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Adaptive Biotechnologies's P/E ratio

Adaptive Biotechnologies's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 45x. In other words, Adaptive Biotechnologies shares trade at around 45x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Adaptive Biotechnologies financials

Revenue TTM	US$92.2 million
Gross profit TTM	US$-7,908,000
Return on assets TTM	-9.77%
Return on equity TTM	-24.57%
Profit margin	-107.96%
Book value	4.133
Market capitalisation	US$6.7 billion

TTM: trailing 12 months

Shorting Adaptive Biotechnologies shares

There are currently 5.2 million Adaptive Biotechnologies shares held short by investors – that's known as Adaptive Biotechnologies's "short interest". This figure is 26.6% up from 4.1 million last month.

There are a few different ways that this level of interest in shorting Adaptive Biotechnologies shares can be evaluated.

Adaptive Biotechnologies's "short interest ratio" (SIR)

Adaptive Biotechnologies's "short interest ratio" (SIR) is the quantity of Adaptive Biotechnologies shares currently shorted divided by the average quantity of Adaptive Biotechnologies shares traded daily (recently around 1.1 million). Adaptive Biotechnologies's SIR currently stands at 4.6. In other words for every 100,000 Adaptive Biotechnologies shares traded daily on the market, roughly 4600 shares are currently held short.

However Adaptive Biotechnologies's short interest can also be evaluated against the total number of Adaptive Biotechnologies shares, or, against the total number of tradable Adaptive Biotechnologies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Adaptive Biotechnologies's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Adaptive Biotechnologies shares in existence, roughly 40 shares are currently held short) or 0.0653% of the tradable shares (for every 100,000 tradable Adaptive Biotechnologies shares, roughly 65 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Adaptive Biotechnologies.

Find out more about how you can short Adaptive Biotechnologies stock.

Adaptive Biotechnologies share dividends

We're not expecting Adaptive Biotechnologies to pay a dividend over the next 12 months.

Adaptive Biotechnologies overview

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test; and Amgen to develop a therapeutic to prevent or treat COVID-19. It serves the life sciences research, clinical diagnostics, and drug discovery customers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.

Frequently asked questions

• What percentage of Adaptive Biotechnologies is owned by insiders or institutions?

  Currently 5.47% of Adaptive Biotechnologies shares are held by insiders and 73.437% by institutions.

• When does the fiscal year end for Adaptive Biotechnologies?

  Adaptive Biotechnologies's fiscal year ends in December.

• Where is Adaptive Biotechnologies based?

  Adaptive Biotechnologies's address is: 1551 Eastlake Avenue East, Seattle, WA, United States, 98102

• What is Adaptive Biotechnologies's ISIN number?

  Adaptive Biotechnologies's international securities identification number is: US00650F1093

• What is Adaptive Biotechnologies's CUSIP number?

  Adaptive Biotechnologies's Committee on Uniform Securities Identification Procedures number is: 00650F109